AJCC	American Joint Committee on Cancer
BOR	best overall response
BRAFi/MEKi	BRAF and MEK inhibitors
CI	confidence interval
CNS	central nervous system
CR	complete response
CRP	C-reactive protein
CTCAE	Common Terminology Criteria for Adverse Events
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
DCR	disease control rate
ECOG	Eastern Cooperative Oncology Group
GEE	generalized estimating equations
HR	hazard ratio
hs-Tn	high-sensitivity troponin
IgG	immunoglobulin G
IL-2	interleukin-2
IND	Investigational New Drug
IQR	interquartile range
LDH	lactate dehydrogenase
LVEF	left ventricular ejection fraction
M1a	distant skin, subcutaneous, or nodal metastases
M1b	lung metastases
M1c	non-CNS visceral metastases
M1d	central nervous system metastases
OOS	out-of-specification
OR	odds ratio
ORR	objective response rate
OS	overall survival
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed death-ligand 1
PFS	progression-free survival
PR	partial response
RECIST	Response Evaluation Criteria in Solid Tumors
SD	stable disease
SE	standard error
TIL	tumor-infiltrating lymphocyte
ULN	upper limit of normal